RE: 'Special bonuses'24 Jan 2023 12:00
I dont see how that's relevant. Tullow are not the same company now, I think you'll struggle to find anyone who works there in a senior position who did when they were based in Dublin.... The Tullow deal was not a good deal IMO, the idea was very good (I think Jubilee is one of the best Africa assets out there, and someone with cash could transform it) but the deal terms were very poor for CNE.
I completely understand that the board lost confidence, but my point has been and still is that the merger is a new board, and most importantly of all (and this is mainly why I exited), not doing it puts the dividend of $620million into doubt, that dividend may now be smaller (maybe not but it 100% has more risk now).
I'm not attempting to stir, I'm merely stating my views based on my research, my personal situation and trying to make sure you see the who picture and not just "the current (or old now) board vs investors".
NewMed is still a good deal IMO, it does depend on your risk / reward appetite though. In these difficult economic times I prefer less risk. As stated I'm an observer now, but i've done a lot of research and modelling on CNE, so I'm very interested to see how this pans out.